259 related articles for article (PubMed ID: 33290885)
1. Immature platelet dynamics correlate with ADAMTS13 deficiency and predict therapy response in immune-mediated thrombotic thrombocytopenic purpura.
Zhu ML; Reeves HM; Maitta RW
Thromb Res; 2021 Feb; 198():72-78. PubMed ID: 33290885
[TBL] [Abstract][Full Text] [Related]
2. Comparison of absolute immature platelet count to the PLASMIC score at presentation in predicting ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura.
Reeves HM; Maitta RW
Thromb Res; 2022 Jul; 215():30-36. PubMed ID: 35617796
[TBL] [Abstract][Full Text] [Related]
3. Absolute immature platelet count dynamics in diagnosing and monitoring the clinical course of thrombotic thrombocytopenic purpura.
Hong H; Xiao W; Stempak LM; Sandhaus LM; Maitta RW
Transfusion; 2015 Apr; 55(4):756-65. PubMed ID: 25370931
[TBL] [Abstract][Full Text] [Related]
4. Absolute Immature Platelet Counts Suggest Platelet Production Suppression during Complicated Relapsing Thrombotic Thrombocytopenic Purpura.
Kundrapu S; Reeves HM; Maitta RW
Acta Haematol; 2021; 144(4):465-469. PubMed ID: 33238282
[TBL] [Abstract][Full Text] [Related]
5. Dynamic changes in absolute immature platelet count suggest the presence of a coexisting immune process in the setting of thrombotic thrombocytopenic purpura.
Stefaniuk CM; Reeves HM; Maitta RW
Transfusion; 2017 Apr; 57(4):913-918. PubMed ID: 28083876
[TBL] [Abstract][Full Text] [Related]
6. Non-O blood group thrombotic thrombocytopenic purpura patients take longer to recover as measured by number of therapeutic plasma exchanges needed for platelet recovery.
Behtaj M; Zhu ML; Bittencourt CE; Ha JP; Maitta RW
Thromb Res; 2020 Jan; 185():78-84. PubMed ID: 31778944
[TBL] [Abstract][Full Text] [Related]
7. Absolute immature platelet count helps differentiate thrombotic thrombocytopenic purpura from hypertension-induced thrombotic microangiopathy.
Zheng Y; Hong H; Reeves HM; Maitta RW
Transfus Apher Sci; 2014 Aug; 51(1):54-7. PubMed ID: 25130726
[TBL] [Abstract][Full Text] [Related]
8. Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura.
Connell NT; Cheves T; Sweeney JD
Transfusion; 2016 Feb; 56(2):354-9. PubMed ID: 26456149
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange.
Peedin AR; Park YA; Mazepa MA; Rollins-Raval MA; Brecher ME; Raval JS
Ther Apher Dial; 2018 Dec; 22(6):662-665. PubMed ID: 30178615
[TBL] [Abstract][Full Text] [Related]
10. Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.
Bentley MJ; Wilson AR; Rodgers GM
Vox Sang; 2013 Nov; 105(4):313-8. PubMed ID: 23662653
[TBL] [Abstract][Full Text] [Related]
11. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
13. Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13.
Kalish Y; Rottenstreich A; Rund D; Hochberg-Klein S
J Thromb Thrombolysis; 2016 Aug; 42(2):155-60. PubMed ID: 26867546
[TBL] [Abstract][Full Text] [Related]
14. Platelets: thrombotic thrombocytopenic purpura.
George JN; Sadler JE; Lämmle B
Hematology Am Soc Hematol Educ Program; 2002; ():315-34. PubMed ID: 12446430
[TBL] [Abstract][Full Text] [Related]
15. Immature platelet dynamics in management of protracted response to therapy of a young pediatric patient with immune-mediated thrombotic thrombocytopenic purpura.
Maitta RW; Reeves HM; Downes KA; He X; Hackney LR; Ahuja SP
Thromb Res; 2023 Aug; 228():145-147. PubMed ID: 37329723
[No Abstract] [Full Text] [Related]
16. Re-examination of 30-day survival and relapse rates in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.
Bittencourt CE; Ha JP; Maitta RW
PLoS One; 2015; 10(5):e0127744. PubMed ID: 26000799
[TBL] [Abstract][Full Text] [Related]
17. COVID 19 infection associated with thrombotic thrombocytopenic purpura.
Dhingra G; Maji M; Mandal S; Vaniyath S; Negi G; Nath UK
J Thromb Thrombolysis; 2021 Aug; 52(2):504-507. PubMed ID: 33904053
[TBL] [Abstract][Full Text] [Related]
18. Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura.
Barrows BD; Teruya J
Arch Pathol Lab Med; 2014 Apr; 138(4):546-9. PubMed ID: 24678685
[TBL] [Abstract][Full Text] [Related]
19. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative.
Bendapudi PK; Li A; Hamdan A; Uhl L; Kaufman R; Stowell C; Dzik W; Makar RS
Br J Haematol; 2015 Dec; 171(5):836-44. PubMed ID: 26314936
[TBL] [Abstract][Full Text] [Related]
20. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.
Furlan M; Robles R; Solenthaler M; Lämmle B
Blood; 1998 Apr; 91(8):2839-46. PubMed ID: 9531594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
